
Biochemical engineer, PhD medical science @karolinskainst and @ugent, #ProstateCancer, #LiquidBiopsy & @ProBioTrial researcher. Views are my own
Ghent, Belgium
Joined November 2016
- Tweets346
- Following642
- Followers363
- Likes1.2K
Pinned Tweet
Privileged seeing the @ProBioTrial published in @NatureMedicine
My sincerest gratitude for all the dedicated doctors, nurses, lab personnel, trial managers, and most importantly, the patients who made this possible🙏
Thank you @komop_tgkanker for making ProBio possible in🇧🇪
🔥📢 The first results from the @ProBioTrial have been published in @NatureMedicine 🚀🌟
ARPIs outperform taxanes in metastatic #ProstateCancer: an outcome-adaptive randomized platform trial 🌟 nature.com/articles/s41591-0…
[1/10]
🚨 Our latest study in @ESMO_Open unveils key genomic alterations that could predict treatment response and outcome in #bladdercancer #MIBC patients receiving neoadjuvant chemotherapy (NAC) before cystectomy. 🧬🧪 #precisiononcology
👉sciencedirect.com/science/ar…
1/5
1
2
103
Using a targeted sequencing approach on 110 MIBC patients, we found focal amplifications on chr6p22.3 — particularly E2F3 and SOX4 — were linked to pathologic response and no recurrences after 5 years.
📈 #Genomics #UroOncology
2/5
1
35
Proud to share the latest insights from the @ProBioTrial
Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant #ProstateCancer
🩸🧬
Full text available on @EurUrolOncol : authors.elsevier.com/sd/arti…
🚨 New Study Alert! 🚨
What if a blood test 🩸 could infer prognosis in advanced prostate cancer? Our latest #ProBio trial study reveals the prognostic power of circulating tumor DNA (ctDNA) 🧬 in #mCRPC
A thread 🧵👇 #CancerResearch #ProstateCancer
[1/8]
A privilege to discuss our 🩸🧬 biomarker-driven @ProBioTrial together with @zklaassen_md
Thank you @urotoday for the invitation 🙏🏻
➡️Visit probiotrial.org or @ProBioTrial for more info!
AR pathway inhibitors vs taxanes in #mCRPC #ProBio trial. @BramDL @ugent joins @zklaassen_md @GACancerCenter to discuss the ProBio trial, a groundbreaking platform study in metastatic prostate cancer. Findings show that AR pathway inhibitors often outperform taxane-based chemo in mCRPC, with outcomes influenced by specific genomic markers. #WatchNow > bit.ly/3YXuh6j
The very talented Dr @Sj0mpie about to embark on a new journey in his academic career. It has been a privilege to mentor you the past 8 years and advance #ProstateCancer research!
Replying to @Sj0mpie
There are a lot of people to thank because a PhD isn't a journey you travel alone.
First, my jury members to critically assess my work (specifically @AdamSharpMedOnc for the great discussion)
Replying to @ProBioTrial
@ProBioTrial in🇧🇪is enkel en alleen maar mogelijk dankzij de steun van @komop_tgkanker en de toegewijde artsen en verpleegkundigen van het @uzgent @azsintjan @azgroeninge @OLVZaalst @gzaziekenhuizen @StLucasBrugge @azoostende @ZOLziekenhuis @AZNIKOLAAS @CHULiege @JessaZiekenhuis
Het bloed van een patiënt voorspelt welke kankerbehandeling het best aanslaat dankzij het @ProBioTrial onderzoek: "Gepersonaliseerde geneeskunde zou de nieuwe standaard moeten worden voor de behandeling van álle tumoren."
ugent.be/nl/actueel/bloed-va…
Don’t give up, but start biomarker-driven patient selection folks! @ProBioTrial 🩸 🧬 might show @Merck the way
Sitting here at #ESMO23 watching randomized data on thousands of patients showing (yet again) that immunotherapy doesn’t improve outcomes for prostate cancer patients. And causes lots of side-effects. Give up folks!
1
6
728
Proud of our @ProBioTrial 🇧🇪 family! Made possible by @komop_tgkanker 🙏🏻
Delighted to share our recent publication: Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant #ProstateCancer mdpi.com/1053174 via @Cancers_MDPI
[1/8]
Metastatic castration-resistant #ProstateCancer is a heterogeneous disease, characterized by common and rare #driver gene alterations. We performed a post hoc analysis of an baseline ctDNA mutational landscape dataset of abiraterone or enzalutamide-treated men with mCRPC.
[2/8]
Cool RCT design by @ResearchWyatt and team to infer optimal ARSi-Taxane sequence strategy in mCRPC
Excited to have our latest prospective biomarker trial PROTRACT (NCT04015622) officially open and accruing! We screened plasma cfDNA from the first patient this week. Thanks to hard work from team of coordinators at @BCCancer and support from @MovemberCA @ResearchPCC.
4
Nice work from @OeyenSteffi in @pcan_journal
➡️Beyond #ACCEPT automated #LiquidBiopsy #CTC enumeration, characterisation of phenotypic #CTC diversity may improve prognostication in patients with advanced #ProstateCancer
nature.com/articles/s41391-0…
@biopsy_liquid @isliquidbiopsy
Congrats @AzadOncology @EdmondMKwan @KohliMask1020 et al for this wonderful work! Very reassuring to see how the cumulative AR burden concept is standing ground. Comprehensive AR profiling is the way forward to study the most commonly perturbed gene in advanced #ProstateCancer
Very proud to present @EUPlatinum paper from my team led by @HeidiFettke @EdmondMKwan describing a novel combined cell-free DNA (cfDNA) and RNA (cfRNA) assay for profiling the Androgen Receptor (AR) in mCRPC europeanurology.com/article/… Thread 1/7
#AI system can diagnose and grade #ProstateCancer as well as internationally leading experts
Online first: #ArtificialIntelligence for #diagnosis and grading of #prostatecancer in biopsies: a population-based, diagnostic study thelancet.com/journals/lanon…
Robin De Putter, onco-geneticist @uzgent, provides excellent overview on #DNA variation, genetic #screening and counseling in #ProstateCancer during @PsaVlaanderen Symposium onco-urology
Replying to @piet_ost
@piet_ost discusses primary and metastasis-directed therapy modalities in metastatic #ProstateCancer during @PsaVlaanderen Symposium onco-urology
Emile Voest from @NKI_nl gives a tour de force with DRUP (Drug Rediscovery Protocol: Expanded use of existing anticancer drugs) #PrecisionMedicine #ESMO19 🙌🏻
Replying to @MarkARubin1
1
@jodebon emphasizes the differentiation of prognostic/predictive biomarkers, the need for novel assys that can identify subclonal transformation, that ATM in the context of PARPi needs more data, and how we can’t escape the complexity of advanced #ProstateCancer #ESMO19
Scott Tomlins from @UMich educating on the essential needs for a genomic tumour board in #ProstateCancer #ESMO19
The beauty of our adaptive #clinicaltrial well explained! This will disentangle prognostic from predictive #Biomarkers and bring #PrecisionMedicine to men with advanced #ProstateCancer @okelidokeli @piet_ost
Replying to @AlessioCrippa
@AlessioCrippa from @karolinskainst gives an excellent overview of the #Statistics engine behind @ProBioTrial during useR! 2019 in Toulouse youtu.be/CmiijpmQqi4










































